A detailed history of Efg Asset Management (North America) Corp. transactions in Alkermes Plc. stock. As of the latest transaction made, Efg Asset Management (North America) Corp. holds 81,761 shares of ALKS stock, worth $2.43 Million. This represents 0.39% of its overall portfolio holdings.

Number of Shares
81,761
Previous 75,864 7.77%
Holding current value
$2.43 Million
Previous $1.83 Million 25.16%
% of portfolio
0.39%
Previous 0.32%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$23.01 - $28.55 $135,689 - $168,359
5,897 Added 7.77%
81,761 $2.29 Million
Q2 2024

Jul 25, 2024

BUY
$23.21 - $27.24 $8,332 - $9,779
359 Added 0.48%
75,864 $1.83 Million
Q1 2024

May 13, 2024

BUY
$26.4 - $32.56 $337,075 - $415,726
12,768 Added 20.35%
75,505 $2.04 Million
Q4 2023

Feb 08, 2024

BUY
$23.37 - $28.68 $159,687 - $195,970
6,833 Added 12.22%
62,737 $1.74 Million
Q3 2023

Nov 02, 2023

SELL
$27.17 - $31.97 $145,033 - $170,655
-5,338 Reduced 8.72%
55,904 $1.57 Million
Q2 2023

Jul 28, 2023

SELL
$28.34 - $33.63 $102,675 - $121,841
-3,623 Reduced 5.59%
61,242 $1.92 Million
Q1 2023

Apr 27, 2023

SELL
$25.31 - $29.02 $91,925 - $105,400
-3,632 Reduced 5.3%
64,865 $1.83 Million
Q4 2022

Feb 03, 2023

SELL
$21.94 - $26.24 $50,418 - $60,299
-2,298 Reduced 3.25%
68,497 $1.79 Million
Q3 2022

Oct 28, 2022

BUY
$22.0 - $31.87 $130,438 - $188,957
5,929 Added 9.14%
70,795 $1.58 Million
Q2 2022

Aug 04, 2022

SELL
$26.4 - $30.54 $146,916 - $169,955
-5,565 Reduced 7.9%
64,866 $1.93 Million
Q1 2022

Apr 26, 2022

BUY
$23.07 - $27.99 $1.62 Million - $1.97 Million
70,431 New
70,431 $1.85 Million

Others Institutions Holding ALKS

About Alkermes plc.


  • Ticker ALKS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 164,254,000
  • Market Cap $4.88B
  • Description
  • Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...
More about ALKS
Track This Portfolio

Track Efg Asset Management (North America) Corp. Portfolio

Follow Efg Asset Management (North America) Corp. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Efg Asset Management (North America) Corp., based on Form 13F filings with the SEC.

News

Stay updated on Efg Asset Management (North America) Corp. with notifications on news.